教育背景（从本科填）

2009年-2013年枣庄学院生物技术专业本科

2013年-2016年复旦大学大学病原生物学专业硕士

2016年-2020年复旦大学大学病原生物学专业博士

研究方向

新型长效HIV融合抑制剂的研究

1: Liu H, Bi W, Wang Q, Lu L, Jiang S. Receptor binding domain based HIV

vaccines. Biomed Res Int. 2015;2015:594109. doi: 10.1155/2015/594109. Epub 2015

Jan 15. PMID: 25667925; PMCID: PMC4312573.

2: Wang Q, Su S, Xue J, Yu F, Pu J, Bi W, Xia S, Meng Y, Wang C, Yang W, Xu W,

Zhu Y, Zheng Q, Qin C, Jiang S, Lu L. An amphipathic peptide targeting the gp41

cytoplasmic tail kills HIV-1 virions and infected cells. Sci Transl Med. 2020

Jun 3;12(546):eaaz2254. doi: 10.1126/scitranslmed.aaz2254. PMID: 32493792.

3: Guo L, Bi W, Wang X, Xu W, Yan R, Zhang Y, Zhao K, Li Y, Zhang M, Cai X,

Jiang S, Xie Y, Zhou Q, Lu L, Dang B. Engineered trimeric ACE2 binds viral spike

protein and locks it in Three-up conformation to potently inhibit SARS-CoV-2

infection. Cell Res. 2021 Jan;31(1):98-100. doi: 10.1038/s41422-020-00438-w.

Epub 2020 Nov 11. PMID: 33177651; PMCID: PMC7656503.

4: Bi W, Xu W, Cheng L, Xue J, Wang Q, Yu F, Xia S, Wang Q, Li G, Qin C, Lu L,

Su L, Jiang S. IgG Fc-binding motif-conjugated HIV-1 fusion inhibitor exhibits

improved potency and in vivo half-life: Potential application in combination

with broad neutralizing antibodies. PLoS Pathog. 2019 Dec 5;15(12):e1008082.

doi: 10.1371/journal.ppat.1008082. PMID: 31805154; PMCID: PMC6894747.

5: Wang Q, Bi W, Zhu X, Li H, Qi Q, Yu F, Lu L, Jiang S. Nonneutralizing

Antibodies Induced by the HIV-1 gp41 NHR Domain Gain Neutralizing Activity in

the Presence of the HIV Fusion Inhibitor Enfuvirtide: a Potential Therapeutic

Vaccine Strategy. J Virol. 2015 Jul;89(13):6960-4. doi: 10.1128/JVI.00791-15.

Epub 2015 Apr 22. PMID: 25903343; PMCID: PMC4

2015年硕士国家奖学金

2016年上海市优秀毕业生